Real-World Evidence and Selecting Optimal Bispecifics in Multiple Myeloma

This is a video synopsis/summary of a Peer Exchange featuring Krina K. Patel, MD, MSc; Amrita Krishnan, MD; Caitlin Costello, MD; Saad Z. Usmani, MD, MBA, FACP; and Rafat Abonour, MD.

The discussion focuses on real-world data with B-cell maturation antigen (BCMA)–targeted bispecific antibodies, which confirms safety and efficacy in patient populations underrepresented in registration trials, such as non-Hispanic African Americans. Nearly half of real-world patients also had extramedullary disease. However, follow-up is still limited in real-world analyses.

In terms of BCMA-directed therapy sequencing, Abonour notes preferentially using a BCMA bispecific first in BCMA-naive patients, while Krishnan and Usmani counter that they would likely start with BCMA-directed chimeric antigen receptor T-cell therapy initially.

Video synopsis is AI-generated and reviewed by OncLive® editorial staff.